Ceramide nanoliposomal - PendreaBio
Alternative Names: Ceramide NanoLiposome; Ceraxa; Ceraxa #1; Ceraxa #2; CNL; KN 001; KN-001 - PendreaBio; KN-01; Nanoliposomal ceramide; PB-1001; PB-1002Latest Information Update: 28 Jul 2024
At a glance
- Originator Keystone Nano
- Developer PendreaBio; University of Virginia
- Class Antineoplastics; Ceramides; Neuroprotectants; Sphingolipids
- Mechanism of Action Undecaprenyl pyrophosphate synthetase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cancer
Highest Development Phases
- Phase I/II Solid tumours
- No development reported Acute myeloid leukaemia; Prostate cancer
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Prostate-cancer in USA
- 01 Nov 2023 Keystone Nano completes a phase I/II trial in Solid tumours (Late-stage disease) in USA (IV) (NCT02834611)
- 28 Oct 2023 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA (Liposomal)